North America Genital Herpes Treatment 麻豆原创 2022-2032 by Virus Type , Drug Type , Route of Administration , Patient Gender , Distribution Channel , and Country: Trend Forecast and Growth Opportunity

Publication ID:

GRM0223038

Publication Date:

February 28, 2023

Pages:

107

Publisher:

Grace 麻豆原创 Data

Countries:

North America [1]

USD 2,800.00

Medical Devices [2]

Diagnostics [3]

Country Overview (Pharma & Healthcare) [4]

Pharma & Healthcare [5]

Description:

North America genital herpes treatment market is projected to grow by 3.9% annually in the forecast period and reach $1,650.9 million by 2032, driven by the rising prevalence of sexually transmitted diseases, changing socio-cultural openness, increasing awareness about HSV infection and its symptoms, improved access to antiviral medications, and the government supports.
Highlighted with 25 tables and 44 figures, this 107-page report 鈥淣orth America Genital Herpes Treatment 麻豆原创 2022-2032 by Virus Type (HSV-1, HSV-2), Drug Type (Acyclovir, Valacyclovir, Famciclovir, Others), Route of Administration (Oral, Topical, Injection), Patient Gender (Female, Male), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Stores), and Country: Trend Forecast and Growth Opportunity鈥� is based on comprehensive research of the entire North America genital herpes treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America genital herpes treatment market in every aspect of the classification from perspectives Virus, Drug Type, Route of Administration, Patient Gender, Distribution Channel, and Country.

Based on Virus Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� HSV-1
鈥� HSV-2

Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Acyclovir
鈥� Valacyclovir
鈥� Famciclovir
鈥� Other Drugs

By Route of Administration, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Oral
鈥� Topical
鈥� Injection

By Patient Gender, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Female
鈥� Male

By Distribution Channel, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Retail Pharmacies
鈥� Hospital Pharmacies
鈥� Online Pharmacies
鈥� Drug Stores

Geographically, the following national/local markets are fully investigated:
鈥� U.S.
鈥� Canada
鈥� Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Virus Type, Drug Type and Distribution Channel over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott
ADLEY FORMULATIONS
Aurobindo Pharma Ltd.
Avet Pharmaceuticals Inc.
Bausch Health Companies
Centurion Remedies
Cipla Ltd.
Eli Lilly & Company
Finecure Pharmaceuticals
GlaxoSmithKline Plc
Glenmark Pharmaceuticals
Macleods Pharmaceuticals
Medico Remedies
Merck & Co., Inc.
Novartis AG
Pfizer
Reddy's Laboratories
Sanofi SA
Teva Pharmaceutical Industries Ltd.
Torrent Pharma
Viatris Inc.
Zeelab Pharmacy
Zydus Pharmaceuticals, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of 麻豆原创 Research Methodology 11
1.2.2 麻豆原创 Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 麻豆原创 Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 麻豆原创 Overview and Dynamics 19
2.1 麻豆原创 Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the 麻豆原创 23
2.2 Major Growth Drivers 25
2.3 麻豆原创 Restraints and Challenges 29
2.4 Emerging Opportunities and 麻豆原创 Trends 32
2.5 Porter鈥檚 Fiver Forces Analysis 36
3 Segmentation of North America 麻豆原创 by Virus Type 40
3.1 麻豆原创 Overview by Virus Type 40
3.2 HSV-1 42
3.3 HSV-2 43
4 Segmentation of North America 麻豆原创 by Drug Type 44
4.1 麻豆原创 Overview by Drug Type 44
4.2 Acyclovir 47
4.3 Valacyclovir 48
4.4 Famciclovir 49
4.5 Other Drugs 50
5 Segmentation of North America 麻豆原创 by Route of Administration 52
5.1 麻豆原创 Overview by Route of Administration 52
5.2 Oral 54
5.3 Topical 55
5.4 Injection 56
6 Segmentation of North America 麻豆原创 by Patient Gender 57
6.1 麻豆原创 Overview by Patient Gender 57
6.2 Female 59
6.3 Male 60
7 Segmentation of North America 麻豆原创 by Distribution Channel 61
7.1 麻豆原创 Overview by Distribution Channel 61
7.2 Retail Pharmacies 63
7.3 Hospital Pharmacies 64
7.4 Online Pharmacies 65
7.5 Drug Stores 66
8 North America 麻豆原创 2022-2032 by Country 67
8.1 Overview of North America 麻豆原创 67
8.2 U.S. 70
8.3 Canada 75
8.4 Mexico 77
9 Competitive Landscape 79
9.1 Overview of Key Vendors 79
9.2 New Product Launch, Partnership, Investment, and M&A 82
9.3 Company Profiles 83
Abbott 83
ADLEY FORMULATIONS 85
Aurobindo Pharma Ltd. 86
Avet Pharmaceuticals Inc. 87
Bausch Health Companies 88
Centurion Remedies 89
Cipla Ltd. 90
Eli Lilly & Company 91
Finecure Pharmaceuticals 92
GlaxoSmithKline Plc 93
Glenmark Pharmaceuticals 94
Macleods Pharmaceuticals 95
Medico Remedies 96
Merck & Co., Inc. 97
Novartis AG 98
Pfizer 99
Reddy's Laboratories 100
Sanofi SA 101
Teva Pharmaceutical Industries Ltd. 102
Torrent Pharma 103
Viatris Inc. 104
Zeelab Pharmacy 105
Zydus Pharmaceuticals, Inc. 106
RELATED REPORTS 107

Companies Mentioned:

Selected Key Players:
Abbott
ADLEY FORMULATIONS
Aurobindo Pharma Ltd.
Avet Pharmaceuticals Inc.
Bausch Health Companies
Centurion Remedies
Cipla Ltd.
Eli Lilly & Company
Finecure Pharmaceuticals
GlaxoSmithKline Plc
Glenmark Pharmaceuticals
Macleods Pharmaceuticals
Medico Remedies
Merck & Co., Inc.
Novartis AG
Pfizer
Reddy's Laboratories
Sanofi SA
Teva Pharmaceutical Industries Ltd.
Torrent Pharma
Viatris Inc.
Zeelab Pharmacy
Zydus Pharmaceuticals, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.